Stay updated with breaking news from Michael Biega. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profi
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery...
- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated -